SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults: Therapeutic Options and Challenges in 2023

Clin Lymphoma Myeloma Leuk. 2023 Jun 27:S2152-2650(23)00195-7. doi: 10.1016/j.clml.2023.06.007. Online ahead of print.ABSTRACTThe therapeutic landscape of Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) for adults has dramatically changed over the past 2 decades; the emergence of newer generations of tyrosine kinase inhibitors and incorporation of targeted immunotherapies into front-line therapy have significantly improved outcomes to the point where an argument can be made that this entity may no longer be considered a high-risk ALL subgroup. In this review article, we discuss different front-line regimens (both intensive and deintensified regimens including chemotherapy-free regimens). We also review disease monitoring strategies, discuss the role of allogeneic hematopoietic stem cell transplantation, and discuss the rapidly changing therapeutic landscape for patients with relapsed disease.PMID:37438208 | DOI:10.1016/j.clml.2023.06.007
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research